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O1. DETECTING AXIAL SPONDYLOARTHRITIS AMONGST
PRIMARY CARE BACK PAIN REFERRALS
Claire Harris1, Denis Remedios2, Tanya Aptowitzer3 and
Andrew Keat1
1Rheumatology Department, Northwick Park Hospital, Harrow,
United Kingdom; 2Radiology Department, Northwick Park Hospital,
Harrow, United Kingdom; 3Physiotherapy Department, Northwick
Park Hospital, Harrow, United Kingdom
Background: Inflammatory back pain (IBP) is an early feature of
ankylosing spondylitis (AS) and its detection offers the prospect of
early diagnosis of AS. However, since back pain is very common but
only a very small minority of back pain sufferers have ASpA or AS,
screening of back pain sufferers for AS is problematic. In early disease
radiographs are often normal so that fulfilment of diagnostic criteria for
AS is impossible though a diagnosis of axial SpA can be made if MRI
evidence of sacroiliitis is present. This pilot study was designed to
indicate whether a cost-effective pick up rate for ASpA/early AS could
be achieved by identifying adults with IBP stratified on the basis of
age.
Methods: Patients aged between 18 and 45 years who were referred
to a hospital physiotherapy service with back pain of more than
3 months duration were assessed for IBP. All were asked to complete
a questionnaire based on the Berlin IBP criteria. Those who fulfilled IBP
criteria were also asked to complete a second short questionnaire
enquiring about SpA comorbidities, to have a blood test for HLA-B27
and CRP level and to undergo an MRI scan of the sacroiliac joints.
This was a limited scan, using STIR, diffusion-weighted, T1 and T2
sequences of the sacroiliac joints to minimize time in the scanner and
cost. The study was funded by a research grant from Abbott
Laboratories Ltd.
Results: 50 sequential patients agreed to participate in the study and
completed the IBP questionnaire. Of these 27 (54%) fulfilled criteria for
IBP. Of these, 2 patients reported a history of an SpA comorbidity - 1
psoriasis; 1 ulcerative colitis - and 3 reported a family history of an SpA
comorbidity - 2 psoriasis; 1 Crohn’s disease. 4 were HLA-B27 positive,
though results were not available for 7. Two patients had marginally
raised CRP levels (6, 10 -NR 5).
19 agreed to undergo MRI scanning of the sacroiliac joints and
lumbar spine; 4 scans were abnormal, showing evidence of bilateral
sacroiliitis on STIR sequences. In all cases the changes met ASAS
criteria but were limited. Of these 4 patients 3 were HLA-B27 positive
but none gave a personal or family history of an SpA-associated
comorbidity and all had normal CRP levels.
Conclusions: This was a pilot study yielding only limited conclusions.
However, it is clear that:
 Screening of patients referred for physiotherapy for IBP is
straightforward, inexpensive and quick.
 It appears that IBP is more prevalent in young adults than overall
population data suggest so that targeting this population may be
efficient.
 IBP questionnaires could be administered routinely during a
physiotherapy assessment.
 HLA-B27 testing in this group of patients with IBP is a suitable
screening tool.
 The sacroiliac joint changes identified were mild and their
prognostic significance is not yet clear so that the value of early
screening needs further evaluation.
Disclosure statement: C.H. received research funding for this study
from Abbott. A.K. received research funding for this study, and
speaker and consultancy fees, from Abbott. All other authors have
declared no conflicts of interest.
O2. VALIDATION OF A SCREENING QUESTIONNAIRE FOR
AXIAL SPONDYLOARTHRITIS IN A UK POPULATION
Louise Hamilton1, Geoffrey Guile3, Abdelghani Belkhiri2,
David Newman2, Andoni Toms2, Alex Macgregor1,3 and
Karl Gaffney1
1Rheumatology Department, Norfolk and Norwich University
Hospital, Norwich, United Kingdom; 2Radiology Department, Norfolk
and Norwich University Hospital, Norwich, United Kingdom;
3Norwich Medical School, University of East Anglia, Norwich,
United Kingdom
Background: Ankylosing spondylitis (AS) is difficult to diagnose early
in the disease course, leading to delayed diagnosis and poor patient
outcomes. Previous attempts to screen populations for AS have
focused on features of inflammatory back pain (IBP), but in practice
such tools lack sensitivity. In this study we devised and validated a
screening questionnaire in 3 patient groups: patients with definite AS,
patients with sacroiliitis and patients with mechanical back pain, with a
view to using this approach in population studies.
Methods: Participants were patients aged 18-60 treated in the
rheumatology department. Three groups were identified from clinic
letters and radiology imaging results: those with AS meeting the
modified New York criteria (mNYC), those with MRI sacroiliitis not
meeting mNYC (i.e. early axial SpA) and those with a ‘mechanical’
diagnosis and degenerative spinal or disc pathology on MRI.
Participants were asked to complete and return a 14 question
survey combining IBP criteria with family history and comorbidities.
Differences in responses were analysed using Chi-squared and
Fisher’s exact tests.
Results: Questionnaires were sent to 100 AS patients (83 replies, 76
analysed), 95 sacroiliitis (SI) patients (59 replies, 46 analysed) and 100
mechanical pain patients (68 replies, 68 analysed). SI patients were
significantly younger than the other groups (mean age 40.4 years (95%
CI 37.0, 43.7) vs 46.9 (44.7, 49.1) for AS and 45.9 (43.8, 48.0) for
mechanical). Mechanical patients were significantly more likely to be
female (31% male vs AS 55% and SI 61%, 2 p¼0.002). Mean
disease duration was 20.3 years (95% CI 18.0, 22.6) for AS and 7.39
(5.6, 9.2) for SI. Sacroiliac joint radiographs were reported by 2
radiologists with weighted kappa 0.49 (95% CI 0.36, 0.62). Agreement
between the 2 MRI readers was measured using intra-class correlation
(ICC¼ 0.71, p<0.001). AS and sacroiliitis patients differed only in
frequency of iritis and inflammatory bowel disease and were
considered together. Insidious onset (p¼ 0.252), alternating buttock
pain (p¼0.229) and waking in the second half of the night (p¼ 0.180)
did not discriminate between those with inflammatory and mechanical
pain. Binary logistic regression was used to develop a model
differentiating inflammatory from mechanical pain. The final model of
male sex, symptom onset by age 33, no radiation of pain, pain
improves as day goes on, pain increases with rest and personal history
of iritis correctly classified 86% of cases with Nagelkerke R2 0.486. By
assigning 1 point for each feature present a numerical score was
calculated and a ROC curve constructed (area under curve 0.911 (95%
CI 0.87, 0.96)). A score 3 has sensitivity 75.6% and specificity 87.9%.
Conclusions: We have developed a model that performs well at
differentiating patients with established AS and non-radiographic
sacroiliitis from those with mechanical back pain. This will now be
used in a primary care prevalence study.
Disclosure statement: K.G. received research grants from Pfizer and
Abbott, attended an MSD conference, and is on the advisory board of
UCB. L.H. received a research grant and honoraria from Pfizer. All
other authors have declared no conflicts of interest.
O3. THE PREVALENCE AND BURDEN OF ANKYLOSING
SPONDYLITIS IN EUROPE: A SYSTEMATIC REVIEW
Linda Morton1, Gareth T. Jones1, Alan G. MacDonald2,
Christina Downham1 and Gary J. Macfarlane1
1Aberdeen Musculoskeletal Research Group (Epidemiology),
University of Aberdeen, Aberdeen, United Kingdom; 2Department
of Rheumatology, Aberdeen Royal Infirmary, Aberdeen,
United Kingdom
Background: For effective provision of health-care, knowledge of
disease distribution is paramount. Although Ankylosing Spondylitis
(AS) prevalence is reported, it is often derived from small-scale
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population studies and may vary considerably by geography. To date,
there has been no attempt to collate these estimates and establish a
single European prevalence of AS. Thus the current study aimed to
determine, in Europe: (a) the prevalence of AS, and (b) to estimate the
overall number of AS patients.
Methods: A systematic literature search was conducted in September
2011 across 5 databases including Medline and Embase using a set of
8 search terms. This search string consisted of both MeSH terms and
text words including, Ankylosing Spondylitis, Spondyloarthropathies
and Prevalence. The search was limited to English but was not limited
by date. Data was extracted on prevalence and 95% confidence
intervals. Where the latter was not presented, these were calculated
from data in the paper. From this the median prevalence for Europe
was computed. Firstly this was applied to the European population, as
per the sum of the most recent censuses for each country
(www.who.int/en/) to estimate the overall burden of AS. A separate
European estimate was obtained based on census data and country-
specific prevalence, or, when this information was missing, prevalence
in neighbouring countries. Thirdly, a final estimate was made, as
above, but where country specific prevalence was missing, using
prevalence from countries with similar HLAB27 prevalence [1].
Results: 5,024 articles were identified during the initial literature
search, of which 361 were considered potentially relevant based on
article titles. On removing duplicates, reviews, non European studies
and those with insufficient data, 14 articles were eligible, providing
data from 11 countries. Prevalence varied from 9 per 10,000 (8.9–9.1)
in the Czech Republic, to 49 per 10,000 (22–77) in Turkey. Separately,
one paper from Germany reported a prevalence of 86 per 10,000, but
was excluded due to major methodological differences compared to
the other studies. The median AS prevalence in Europe was 23.5 per
10,000 equating to 1.63 million individuals.
The alternative methods of computing burden of AS in Europe
yielded estimates of 1.65 and 1.71 million patients respectively, giving
a mean (across all 3 methods) of 1.66 million.
Conclusions: This study presents a AS prevalence estimate for the
whole of Europe by collating all available data published to date and is
the first study to estimate the current burden of AS. Further sensitivity
analysis, using slightly different assumptions for countries with no
prevalence data, result in remarkably similar estimates of the total
population, with a mean of 1.66 million patients. With costs of new
therapies and impact on work disability, this represents a considerable
burden on health services.
Disclosure statement: G.J. received research grants and speaker
fees from Abbott, and research grants from Pfizer. G.M. received
research grants from Abbott and Pfizer. All other authors have
declared no conflicts of interest.
1. Cavalli-Sforza LL. The History and Geography of Human Genes
1994.
O4. WORK DISABILITY IN ESTABLISHED PSORIATIC
ARTHRITIS: A CROSS-SECTIONAL STUDY USING THE
WORK PRODUCTIVITY ACTIVITY INDEX
William Tillett1, Deepak Jadon1, Dinny Wallis1, Luisa Costa1,
Nicola Waldron1, Nina Griffith1, Charlotte Cavill2,
Eleanor Korendowych1, Corinne de Vries2 and Neil McHugh1,2
1Rheumatology, Royal National Hospital for Rheumatic Diseases,
Bath, United Kingdom; 2Pharmacy and Pharmacology, University
of Bath, Bath, United Kingdom
Background: There is increasing awareness that work disability (WD)
is an important outcome measure in arthritis. The burden of WD in
Rheumatoid arthritis (RA), Ankylosing spondylitis (AS) and Psoriasis
(PsO) is well established however the data in psoriatic arthritis (PsA) is
sparse and there is no well validated outcome measure. The Work
Productivity Activity Index- Specific Health Questionnaire (WPAI-SHP)
has been used to measure WD in PsO and AS. We set out to explore
the feasibility and construct validity of the WPAI-SHP in PsA.
Methods: This cross sectional study was undertaken as part of the
Long term Outcomes in Psoriatic Study II (LOPAS II). 380 patients with
PsA were sent the following questionnaires by post in January 2011;
Health Assessment Questionnaire (HAQ-DI- physical function), Patient
Global (PtG), EuroQol (EQ5D- quality of life), Dermatology Life Quality
Index (DLQI- skin-specific quality of life), FACIT-fatigue (Fatigue),
WPAI-SHP (WD) and an additional work questionnaire. The WPAI-SHP
is comprised of six questions and reports WD as percentages of;
absenteeism (work time missed), presenteeism (impairment at work/
reduced effectiveness) and productivity loss (overall work impairment/
absenteeism plus presenteeism). Correlations were explored using
Spearman correlation coefficients (cc).
Results: 270 (71%) participants responded, 50% male, mean age
58yrs (standard deviation- SD 17.2), mean PsA duration 17yrs (SD
10.6). 70% of respondents were of UK working age (18-65yrs), of these
80% (179) were in work. Of those not working 23% were not working
because of their PsA, 21% were off work for other reasons and 56%
were retired. Of the 179 respondents in work absenteeism, presentee-
ism and productivity loss were 4.7%, 21.1% and 24.0% respectively,
median PtG 2.0 (Interquartile range-IQR 1.0), median Pain VAS 2.3
(IQR 3.3), median HAQ-DI 0.5 (IQR 1.1), median EQ5D 0.73 (IQR 0.17),
median DLQI 2.0 (IQR 3.0) and median FACIT fatigue 40.0 (IQR 17.7)
Correlations of WD with these outcomes are reported in Table 1.
Presenteeism and productivity loss both show strong correlation with
the PtG, HAQ-DI, EQ5D and FACIT-fatigue. WD was not correlated
with type of work, age, sex, PsA duration, the presence of erosive
disease or spinal disease.
Conclusions: There are significant levels of unemployment due to PsA
in those of working age as well as high levels of presenteeism and
productivity loss in those who remain at work. The WPAI was found to
be feasible and correlation with measures of physical function, quality
of life and fatigue provides initial evidence for the construct validity of
the WPAI in PsA.
TABLE 1 Spearman correlations between WPAI-SHP and health status outcomes
Patient
global
Pain
VAS
HAQ
DI
EQ5Dindex DLQI FACIT-
fatigue
Absenteeism 0.16 0.13 0.36* 0.24* 0.1 0.24*
Presenteeism 0.56* 0.43* 0.61* 0.64* 0.26* 0.64*
Productivity loss 0.56* 0.43* 0.66* 0.65* 0.15 0.64*
*p<0.01.
Disclosure statement: W.T. received a research grant from Abbott.
All other authors have declared no conflicts of interest.
O5. INFLUENCE OF LEFLUNOMIDE ON THE LEVELS OF
MATRIX METALLOPROTEINASE-3 AND PYRIDINOLINE
IN PATIENTS WITH PSORIATIC ARTHRITIS
Oleg Iaremenko1 and Dmytro Fedkov1
1Department of Internal Medicine, National Medical University
O.O.Bogomolets, Kyiv, Ukraine
Background: Conventional laboratory markers of inflammation
(C-reactive protein (CRP), erythrocyte sedimentation rate (ESR)) at
PsA correlate with the severity of lesions of the musculoskeletal
system worth than in rheumatoid arthritis. This greatly complicates the
paraclinical assessment of the efficiency of treatment and degree of
destructive changes in connective tissue (DCT) in the PsA, especially
when short-termed observations are provided. This study is aimed to
evaluate the impact of Leflunomide (Lef) alone and in combination with
Methotrexate (MTX) or Sulfasalazine (SS) on the clinical activity and
level of MMP-3 and PYR in PsA patients (pts).
Methods: The study involved 63 PsA pts with peripheral arthritis. 32
pts were receiving Lef alone and 31 - Lef in addition to MTX (19) or SS
(13). Response was evaluated according to PsARC criteria, Health
Assessment Questionnaire (HAQ), DAS and DAS CRP. Serum levels of
MMP-3 and PYR were conducted at baseline and after 3 months of the
treatment.
Results: After 3 months the decrease of MMP-3 (19.6%) and PYR
(8.6%) levels was observed. The changes were more striking in the
group of PsARC responders (65% of pts): levels of MMP-3 decreased
by 28.6%, PYR - by 10.9%, and accompanied by decreased the
number of swollen and tender joints - by 72.6% and 63.1%, HAQ - by
37.8%, ESR and CRP - by 20.6% and 11%, DAS and DAS CRP - by
38.2% and 10.7%. The changes of PYR and MMP-3 in the group of
non-responders were not significant. Prior to treatment the levels of
MMP-3 and PYR in PsARC responders were 18.28.80 ng/ml and
2.110.67 nmol/l and were higher compared with non-responders by
18.9% and 7.6% (both p<0,01). Reduction of MMP-3 after treatment
was significantly greater in pts receiving Lef in addition to MTX or SS -
24.4% vs 13.0% in pts receiving Lef alone. Statistical differences in the
dynamics of PYR, ESR and CRP between patients treated with Lef in
addition to MTX or SS and Lef alone were not registered. Changes in
MMP-3 level positively correlated with the dynamics of the number of
swollen joints (r¼ 0.29, p<0.03) and duration of morning stiffness
(r¼0.52, p<0.001), while the dynamics of the other laboratory
parameters (ESR, CRP, PYR) was not correlated with the changes of
clinical parameters or MMP-3.
Conclusions: Significant reduction in levels of MMP-3 and PYR under
the influence of treatment shows the ability of Lef to lower levels of
inflammation and bone destruction in pts with PsA. Among the
laboratory markers of inflammation and DCT only the dynamics of
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MMP-3 levels correlates with the changes in arthritis activity and
confirmes the higher efficacy of Lef in addition to MTX or SS vs Lef
alone and in the best way shows the differences between the PsARC
responders and non-responders. This suggests that MMP-3 may be
acceptable laboratory marker for assessing anti-inflammatory/anti-
destructive action of DMARDs in PsA pts in short-term observations.
Disclosure statement: All authors have declared no conflicts of
interest.
O6. EVALUATION OF EFFICACY AND SAFETY OF
SECUKINUMAB IN THE TREATMENT OF PATIENTS WITH
MODERATE-TO-SEVERE ANKYLOSING SPONDYLITIS
Paul Emery1, Dominique Baeten2, Joachim Sieper3, Jurgen Braun4,
D. van der Heijde5, Iain McInnes6, Jaap Van Laar7, R. Landewe8,
Bryan P. Wordsworth9, Jurgen Wollenhaupt10, Herbert Kellner11,
I. Paramarta2, Arthur Bertolino1,2, Andrew M. Wright1,3 and
Wolfgang Hueber1,2
1Department of Medicine, University of Leeds, Leeds, United
Kingdom; 2Academic Medical Center, University of Amsterdam,
Amsterdam, Netherlands; 3Department of Gastroenterology, Charite
Campus Benjamin Franklin, Berlin, Germany; 4Department of
Medicine, Rheumazentrum Ruhrgebiet, Herne, Germany;
5Department of Rheumatology, Leiden University Medical Center,
Leiden, Netherlands; 6Glasgow Biomedical Research Centre,
University of Glasgow, Glasgow, United Kingdom; 7Department of
Medicine, Newcastle University, Newcastle upon Tyne, United
Kingdom; 8Department of Medicine, Maastricht University Medical
Center, Maastricht, Netherlands; 9Department of Medicine, Nuffield
Orthopaedic Centre, Oxford, United Kingdom; 10Klinik fu¨r
Rheumatologie, Eilbeck Hospital, Hamburg, Germany; 11Department
of Medicine, Center for Inflammatory Joint Diseases, Munich,
Germany; 12TM Dermatology, Novartis Institutes for BioMedical
Research, Basel, Switzerland; 13M&S Statistics, Novartis Pharma AG,
Basel, Switzerland
Background: The current proof of concept study explored the efficacy
and safety of secukinumab (AIN457), a fully human monoclonal
antibody, for targeted IL-17A blockade as a novel therapeutic strategy
in the treatment of moderate-to-severe ankylosing spondylitis (AS).
Methods: A2209 (NCT00809159) is a 28-week (wk), double blind,
placebo controlled study. 30 patients with active AS were randomized
(4:1) to receive two i. v. infusions of secukinumab 10 mg/kg or placebo,
given 3 weeks apart. Primary endpoint was the proportion of patients
achieving the Assessment of SpondyloArthritis international Society
(ASAS) 20 response at wk 6. A Bayesian method for the primary
endpoint analysis was applied and included historical placebo
information from 8 representative AS trials. Final data will be
presented.
Results: Demographics and baseline characteristics were comparable
between groups. Five patients (3 on placebo and 2 on secukinumab)
discontinued the study prior to the primary endpoint analysis (wk 6),
mostly due to unsatisfactory therapeutic effect. After randomization,
efficacy data of one patient was not available due to a protocol
violation. At wk 6, 14/23 (61%) secukinumab-treated patients achieved
ASAS20 responses versus 1/6 (17%) placebo-treated patients (prob-
ability of positive treatment difference¼99.8%; 95% credible interval
11.5%, 56.3%). At wk 6, 30% secukinumab-treated patients achieved
ASAS40 response and 35% achieved ASAS5/6 response. Mean
BASDAI in secukinumab-treated patients was reduced by 1.8
(individual reductions ranging from 5.6 to 0.8) at wk 6. ASAS
response rates were greatest at the primary endpoint at wk 6, and
declined thereafter up to end of study at wk 28, consistent with the
preliminary dose regimen of only two doses of 10 mg/kg given at days
1 and 22, as chosen for this proof-of-concept study. Post-hoc
analyses of subgroups showed superior response rates with TNFi
naive patients (11/13; 85%) compared to TNFi pre-exposed patients
(3/10; 30%). PK profile for secukinumab was as expected for an IgG1
therapeutic antibody and similar to the profiles seen in other
indications. The incidence of adverse events was similar to those
observed in previous secukinumab studies. Overall, 30 infections (22
mild, 7 moderate, 1 severe) were reported in 18 patients. Two SAEs
(placebo: blood pressure increased; secukinumab: subcutaneous
abscess) and no death were reported in this study.
Conclusions: The primary endpoint of this study was met, as
secukinumab induced ASAS20 responses were significantly higher
than placebo at wk 6. No early safety signals were noted in this study
population. Data presented here suggest that secukinumab may be
useful for the treatment of active ankylosing spondylitis and thereby
warrant larger long term studies on safety and efficacy.
Disclosure statement: D.B. received grants and research support
from Abbott, Pfizer and Centocor. A.B. was formerly employed by
Novartis. J.B. is a consultant to VirtualScopics. P.E. is a consultant to
Merck, Pfizer, Roche, Abbott, Bristol-Myers Squibb, Lilly and Takeda.
W.H. is an emloyee of Novartis. R.L. received grants and research
support from Amgen, Abbott, Centocor, Schering, Pfizer, Wyeth and
UCB, and is a consultant to Amgen, Abbott, Centocor, Schering,
Pfizer, Wyeth, UCB, Merck and Roche. I.M. received grants and
research support from Merck, Roche, Pfizer and Bristol-Myers Squibb.
J.S. received grants and research support from Pfizer, Merck, Abbott,
sanofi-aventis and Bristol-Myers Squibb, and is a member of the
speakers bureaus of Pfizer, Merck, Abbott, sanofi-aventis and Bristol-
Myers Squibb. D.V. received grants and research support from Abbott,
Amgen, Bristol-Myers Squibb, Centocor, Chugai, Merck, Novartis,
Pfizer, Roche, sanofi-aventis, Schering-Plough, UCB and Wyeth, and
is a consultant to Abbott, Bristol-Myers Squibb, Centocor, Chugai,
Merck, Novartis, Pfizer, Roche, sanofi-aventis, Schering-Plough, UCB
and Wyeth. J.V. received grants and research support from Roche, is a
consultant to Roche, and is a member of Roche’s speakers bureau.
B.W. is a member of the speakers bureaus of Abbott and Merck. A.W.
is an employee of Novartis. All other authors have declared no conflicts
of interest.
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O7. HAND OSTEOARTHRITIS PAIN HAS PERIPHERAL AND
CENTRAL COMPONENTS DEMONSTRATED BY ALGOMETER
SCORES AND FUNCTIONAL MRI
Nidhi Sofat1,2, Cori Smee2, Monika Hermansson2, Julekha Wajed1,
Kaushik Sanyal1, Patrick Kiely1, Matthew Howard3,
Franklyn A. Howe4 and Thomas R. Barrick4
1Rheumatology, St George’s, University of London, London, United
Kingdom; 2Biomedical Sciences, St George’s, University of London,
London, United Kingdom; 3Institute of Psychiatry, King’s College
London, London, United Kingdom; 4Clinical Sciences, St George’s,
University of London, London, United Kingdom
Background: Hand osteoarthritis (OA) is a prevalent condition typified
by chronic pain and reduced function. We hypothesized that hand OA
subjects have enhanced sensitivity and firing of peripheral nociceptors
in the hand, thereby potentiating chronic pain. In this study we aimed
to: 1. evaluate the characteristics of local pain in hand OA; 2. assess if
central sensitization contributes to pain perception in our hand OA
cohort.
Methods: Participants with proximal and distal interphalangeal joint
(PIP and DIP) hand OA and controls were recruited (n¼13 per group
with 780 hand joints assessed in total). Clinical scores including VAS
(visual analogue score), HAQ (health assessment questionnaire),
Kellgren-Lawrence (K-L) scores for radiological severity and pain
thresholds using algometers (Wagner, USA) were measured. Central
brain pain processing was tested with a standardized finger flexion-
extension (FFE) task which reproduced pain in hand OA subjects but
not controls. Functional MRI (fMRI) was performed with a 1.5T GE
scanner (General Electric Systems, Milwaukee, USA) during the FFE
task. Activation of brain regions was evaluated using FMRIB software
(www.fmrib.ox.ac.uk/fsl). Grouped data analysis with a z-statistic
threshold of 2.3 and multiple comparisons correction at p<0.05 was
used.
Results: Hand OA participants reported pain despite 92% taking oral
analgesics. The mean VAS in the hand OA group was 59.31 mm 8.19
compared with 4.00 mm1.89 in controls. The hand OA cohort had
higher HAQ scores than controls (p<0.0001) showing significant
functional impairment. Objective pain measures by algometer in 30
hand joint regions per subject showed significantly lower pain
thresholds in the OA group versus controls (p<0.0001). Radiological
changes occurred mainly in the PIP/DIP joints, as demonstrated by a
K-L score of 3-4 in 17.3% of all DIP and PIP joints assessed in
comparison to only 3% of CMC joints and 0.27% of MCP joints. In our
functional MRI analysis, the results of the mean group activation signal
thresholded to statistical significance (p<0.05) demonstrated
increased activation of the thalamus, cingulate gyrus, frontal and
somatosensory cortex in the hand OA group. The regions activated in
hand OA subjects are all recognized regions of brain pain processing.
In contrast, activation in the control group was only observed in the
motor cortex, as would be expected with the FFE task, but not in other
brain regions associated with pain processing.
Conclusions: Hand OA subjects have lower pain thresholds globally in
their hands compared with controls, demonstrated by algometer
scores which showed low pain thresholds even in hand joints where
radiological severity was low. Our fMRI data also demonstrate
evidence of central sensitization in our cohort of hand OA subjects.
We therefore conclude that algometers and functional neuroimaging
measure distinct components of hand OA pain and are useful
biomarkers of disease.
Disclosure statement: All authors have declared no conflicts of
interest.
O8. ULTRASOUND FEATURES OF OSTEOPHYTES AND
CARTILAGE THICKNESS AT THE KNEE ARE ASSOCIATED
WITH PAIN AND FUNCTIONAL IMPAIRMENT: THE
NEWCASTLE THOUSAND FAMILIES STUDY
Ajay M. Abraham1, Mark S. Pearce1, Kay D. Mann1, Roger
M. Francis3 and Fraser Birrell2
1Institute of Health and Society, Newcastle University, Newcastle
upon Tyne, United Kingdom; 2Musculoskeletal Research Group,
Institute of Cellular Medicine, Newcastle University, Newcastle upon
Tyne, United Kingdom; 3Institute for Ageing and Health, Newcastle
University, Newcastle upon Tyne, United Kingdom
Background: Previous studies have shown contradictory results for
the association of structural changes of osteoarthritis (OA) on imaging
with clinical symptoms. We performed a comparison of ultrasound
features of knee OA with clinical symptoms among members of the
Newcastle Thousand Families birth cohort.
Methods: Participants from the cohort aged 63 years (born in May-
June 1947), had both knees scanned by a trained musculoskeletal
sonographer. Ultrasound protocols were derived from EULAR guide-
lines. Knee osteophytes (yes/no), minimum femoral cartilage thickness
in right knee (mm) and effusion >4 mm (yes/no) were recorded. These
data were analysed in relation to pain, stiffness and function in the
lower limbs as reported by participants using the WOMAC ques-
tionnaire. Each of the three WOMAC subscales was subdivided in to
four categories of severity. Logistic and linear regression was used to
calculate the association of features of knee OA with clinical
symptoms. Adjustment for potential confounders such as BMI, sex
and presence of knee effusion was also performed.
Results: 311 participants were scanned; 55% women, mean BMI was
27.9 kg/m2 (sd¼4.9). Prevalence of knee osteophytes was 30%, mean
right knee minimum femoral cartilage thickness was 1.47 mm;
prevalence of knee effusions was 22%. Those in the highest category
of pain had an OR of 4.42 for osteophytes (95% CI 2.17, 8.98) when
compared to those without knee pain. Similarly, those with severe
stiffness had an OR of 4.21 (95% CI 2.01, 8.83) and those with physical
dysfunction had an OR of 4.15 (95% CI 1.96, 8.80) for knee
osteophytes when compared to those with no symptoms. These
estimates were reduced in magnitude but remained statistically
significant after adjustment for BMI and sex. Minimum cartilage
thickness was associated with pain (adjusted co-efficient 0.11; 95%
CI 0.20, 0.01) and reduced physical function (adjusted co-efficient
0.13; 95% CI 0.24, 0.02) but not stiffness; when comparing those
in the most severe symptom category with those without symptoms.
Knee effusion had no association with any of the three subscales of the
WOMAC questionnaire.
Conclusions: This is the first study to compare ultrasound features of
OA with clinical symptoms in a population based cohort. The presence
of knee osteophytes had a positive association with pain, stiffness and
functional impairment. Femoral cartilage thickness in the knee had an
inverse association with pain and functional impairment. However,
there was no association of knee effusion with pain, stiffness or
function. The associations of ultrasound detected osteophytes and
cartilage thickness with clinical symptoms improve our understanding
of the relationship between symptoms and structural changes in knee
OA, which is strong. This also demonstrates the potential utility of
ultrasound in prospective population based epidemiological studies of
OA as well as in clinical practice.
Disclosure statement: All authors have declared no conflicts of
interest.
O9. THE DIAGNOSTIC UTILITY OF SALIVARY GLAND
ULTRASOUND FOR THE INVESTIGATION OF SJO¨GREN’S
SYNDROME
Andrew Carr1, Iain Macleod1 and Wan-Fai Ng2
1Dental and Maxillofacial Radiology, Newcastle Dental Hospital,
Newcastle upon Tyne, United Kingdom; 2Musculoskeletal Research
Group, Institute of Cellular Medicine, Faculty of Medical Sciences,
Newcastle University, Newcastle upon Tyne, United Kingdom
Background: Primary Sjo¨gren’s syndrome (PSS) is a chronic multi-
system condition characterized by oral and ocular dryness, muscu-
loskeletal pain and fatigue. Although xerostomia is a cardinal symptom
of Sjo¨gren’s Syndrome, it can also be caused by medications,
radiotherapy, various other medical conditions or idiopathic.
An imaging technique that can reliably discriminate PSS-related
xerostomia and oral dryness due to other conditions will be invaluable
in the diagnosis of PSS.
Traditional techniques for salivary imaging such as sialography or
scintiscans involve exposure to radiation, invasive and can be
uncomfortable for patients. In this study, we present our experience
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of using salivary gland ultrasound in the assessment of patients
presenting with a dry mouth or suspected PSS.
Methods: 200 patients who had attended the Department of Dental
and Maxillofacial Radiology, Newcastle Dental Hospital between May
2010 and May 2011 for ultrasound investigation were identified using
the hospital’s electronic patient administration system. 74 out of the
200 imaging requests were for patients presenting with ‘dry mouth’,
‘xerostomia’ or suspected Sjo¨gren’s Syndrome. The medical records
including the final diagnosis, clinical history and laboratory data of
these patients were reviewed. All patients underwent ultrasound
examination of the major salivary glands using a standardized
approach performed by one of the two co-authors (IM and AC).
Parotid and submandibular glands were assessed for gland echogen-
icity,(normal or presence of hypoechoic foci), fibrosis running through
parenchyma, gland demarcation and presence of lymph nodes.
Vascularity changes within enlarged (>1 cm) lymph nodes were also
assessed for aberrant blood flow patterns.
Results: Of the 74 patients who have undergone salivary gland
ultrasound for xerostomia or suspected PSS, 34 patients have a final
diagnosis of PSS, of whom 29 also had positive ultrasound features of
SS.
Statistical analysis of the data captured demonstrates a sensitivity
of 0.906, specificity of 0.881, with positive and negative predictive
values as 0.853 and 0.925 respectively.
Gland appearances of the Sjo¨gren’s patient were multiple
hypoechoic foci, marked fibrosis through the parenchyma and
indistinct gland margins, although the severity of each of these factors
can vary considerably between patients.
Conclusions: Ultrasound is a useful imaging technique for the
evaluation of parenchymal change within the major salivary glands. It
has been found to be a specific, effective, non-invasive and relatively
cost-effective investigation, involving no ionizing radiation and with no
obvious complications. However, further work is required to assess the
specificity and sensitivity of the modality in the assessment of this
complex clinical problem.
Disclosure statement: All authors have declared no conflicts of
interest.
O10. LONG-TERM RADIOGRAPHIC OUTCOME IN
PSORIATIC ARTHRITIS PATIENTS TREATED WITH
GOLIMUMAB: 104 WEEK RESULTS FROM THE GO-REVEAL
STUDY
Arthur Kavanaugh1, Desiree van der Heijde2,
Chandrabhusan Chattopadhyay3, Dafna Gladman4, Philip Mease5,
Iain McInnes6, Gerald Krueger7, Weichun Xu8, Neil Goldstein8 and
Anna Beutler8
1Immunology, University of California, San Diego, San Diego,
California, United States of America; 2Rheumatology, Leiden
University Medical Center, Leiden, Netherlands; 3Rheumatology,
Wrightington Hospital, Wigan, United Kingdom; 4Rheumatology,
Toronto Western Hospital, Toronto, Ontario, Canada;
5Rheumatology, Swedish Medical Center/ University of Washington,
Seattle, Washington, United States of America; 6Rheumatology,
University of Glasgow, Glasgow, United Kingdom; 7Dermatology,
University of Utah Health Sciences Center, Salt Lake City, Utah,
United States of America; 8Immunology, Janssen Research and
Development, Inc., Malvern, Pennsylvania,United States of America
Background: Golimumab (GLM), a human monoclonal anti-TNFa
antibody administered as every 4 weeks subcutaneous injections
demonstrated long-term clinical efficacy and acceptable safety
through wk104. The effect of GLM on inhibition of progression of
structural damage PsA pts has been shown through wk52. Week 104
radiographic results are being reported now.
Methods: Adult PsA pts with 3 swollen & 3 tender joints (SJC/TJC)
were randomized to receive SC placebo (PBO) or GLM 50 mg or
100 mg q4 wks. At wk16, pts with <10% improvement in SJC/TJC’s
entered early escape (EE) in a double-blinded manner to GLM 50 mg
(PBO pts) or GLM 100 mg (GLM 50 mg pts). All pts randomized to PBO
received GLM 50 mg from wk24 through wk104. Pts on GLM 50 mg
could be dose-escalated based on the investigator’s judgment to GLM
100 mg after unblinding at wk52. Radiographs of the hands and feet
were read at wks 0, 52, and 104. Erosions and joint space narrowing
were evaluated by two independent readers unaware of treatment and
image time sequence using the van der Heijde-Sharp (vdH-S) method
modified for PsA. Data were analysed based on randomized groups
(analyses for PBO group includes pts who qualified for EE, crossed-
over to GLM 50 mg and pts were dose-escalated from GLM 50 mg to
GLM 100 mg; GLM 50 mg group includes pts who qualified for EE and
pts who were dose-escalated to GLM 100 mg; GLM 100 mg group
includes pts who qualified for EE). Due to lack of adequate control arm,
no statistical comparisons were performed at wk52 or wk104.
Results: 405 pts were enrolled. Mean age was 46–48 yrs, median
SJC/TJC’s were 12–14/22–24, HAQ scores were 1.0–1.1, CRP
levels were 0.6 mg/dL, and mean (median) total vdH-S scores were
16.34–22.99 (9.00–10.50). Change from baseline to wk52 in total
scores were [meanþSD (median, IQR)]: 0.10þ1.88 (0.00 [0.00, 0.50]),
0.30þ1.65 (0.00 [-0.50, 0.00]), and 0.35þ 1.70 (0.00 [0.00, 0.00])
for the PBO, GLM50mg, and GLM100 mg groups, respectively.
Change from wk52 to wk104 in total score were: 0.03þ1.59 (0.00
[0.00, 0.00]), 0.10þ0.10 (0.00 [0.00, 0.00]), and 0.02þ0.71 (0.00
[0.00, 0.00]), respectively. Change from baseline to wk104 in total
score were: 0.08þ 3.19 (0.00 [-0.50, 0.50]), 0.39þ2.04 (0.00 [-0.90,
0.00]), and 0.32þ 1.873 (0.00 [-0.50, 0.00]), respectively.
Conclusions: GLM 50 mg and 100 mg treated patients with active PsA
showed no to minimal evidence of radiographic disease progression
through wk104.
Disclosure statement: A.B. is an employee of Janssen. C.C. is an
investigator for Janssen. D.G. is an investigator for Janssen. N.G. is an
employee of Janssen. A.K. is an investigator for Janssen. G.K. is
an investigator for Janssen. I.M. is an investigator for Janssen. P.M.
is an investigator for Janssen. D.V. is an investigator for Janssen. W.X.
is an employee of Janssen. All other authors have declared no conflicts
of interest.
O11. EARLY EFFECT OF SECUKINUMAB IN REDUCING
SPINAL INFLAMMATION AS DETECTED BY MAGNETIC
RESONANCE IMAGING IN PATIENTS WITH ANKYLOSING
SPONDYLITIS
Jaap Van Laar1, Xenofon Baraliakos2, Jurgen Braun2,
Didier D. Laurent3, Dominique Baeten4, D. van der Heijde5,
Joachim Sieper6, Paul Emery7, Iain McInnes8, R. Landewe9,
Bryan P. Wordsworth10, Ju¨rgen Wollenhaupt11, Herbert Kellner12,
Andrew M. Wright13, Sandro Gsteiger13 and Wolfgang Hueber3
1Department of Medicine, Newcastle University, Newcastle upon
Tyne, United Kingdom; 2Department of Medicine, Rheumazentrum
Ruhrgebiet, Herne, Germany; 3Translational Medicine Dermatology,
Novartis Institutes for BioMedical Research, Basel, Switzerland;
4Academic Medical Center, University of Amsterdam, Amsterdam,
Netherlands; 5Department of Rheumatology, Leiden University
Medical Center, Leiden, Netherlands; 6Department of
Gastroenterology, Charite` Campus Benjamin Franklin, Berlin,
Germany; 7Department of Medicine, University of Leeds, Leeds,
United Kingdom; 8Glasgow Biomedical Research Centre, University
of Glasgow, Glasgow, United Kingdom; 9Department of Medicine,
Maastricht University Medical Center, Maastricht, Netherlands;
10Department of Medicine, Nuffield Orthopaedic Centre, Oxford,
United Kingdom; 11Klinik fu¨r Rheumatologie, Eilbeck Hospital,
Hamburg, Germany; 12Department of Medicine, Center for
Inflammatory Joint Diseases, Munich, Germany; 13M&S Statistics,
Novartis Pharma AG, Basel, Switzerland
Background: Secukinumab, a fully human IgG1k anti-IL17A mono-
clonal antibody, showed significant improvement of clinical signs and
symptoms of ankylosing spondylitis (AS). Here, we evaluated the
clinical effects of secukinumab (10 mg/kg i.v.) on spinal inflammation,
as detected by magnetic resonance imaging (MRI) in patients with AS.
Methods: A2209 (NCT00809159) is a 28-week double blind, placebo
controlled study. 30 patients with active AS were randomized (4:1)
to receive two i. v. infusions of secukinumab 10 mg/kg or placebo,
given 3 weeks apart. Primary endpoint was the proportion of patients
achieving Assessment of SpondyloArthritis international Society
(ASAS) 20 response at week 6. Sagittal MRI of the spine was
performed including T1- and short tau inversion recovery (STIR)
sequences at baseline (BL), week 6 and week 28. Images were
analysed by an independent reader, who was blinded to treatment
allocation and chronology of images, using the Berlin modification of
the AS spinal MRI (ASspiMRI-a) scoring system. Changes between
baseline and follow-up in each treatment arm were evaluated by
Wilcoxon signed-rank test.
Results: 27 patients (22 secukinumab; 5 placebo) had evaluable MR
images at baseline. Due to early discontinuation, 2 patients on placebo
at week 6 and 6 patients on secukinumab at week 28 were not
analysed for MRI. At week 6, a higher proportion of patients achieved
ASAS20 response with secukinumab versus placebo (61% [n¼14/23]
vs. 17% [n¼1/6]). Improvement in mean Berlin MRI scores with
secukinumab was seen as early as week 6 and sustained up to week
28 versus placebo (BL: 9.2, wk6: 6.7, wk28: 5.7 vs. BL: 20.6, wk 6:
21.0, wk28: 19). Early improvements at week 6 were especially noted
in patients with higher baseline scores. Only minor changes were seen
in patients on placebo.
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Conclusions: Results of this study suggest that treatment with only 2
infusions of secukinumab substantially reduces spinal inflammation as
detected by MRI. MRI score improvements were seen as early as
week 6 and sustained up to week 28. Results are consistent with MRI
findings obtained in previous AS trials with TNF blockers. These results
support that secukinumab may be a potential treatment for patients
with active AS.
Disclosure statement: D.B. received grants and research support
from Abbott, Pfizer and Centocor. P.E. is a consultant to Merck, Pfizer,
Roche, Abbott, Bristol-Myers Squibb, Lilly and Takeda. S.G. is an
employee of Novartis. W.H. is an employee of Novartis. R.L. received
grants and research support from Amgen, Abbott, Centocor, Schering,
Pfizer, Wyeth and UCB, and is a consultant to Amgen, Abbott,
Centocor, Schering, Pfizer, Wyeth, UCB, Merck and Roche. D.L. is an
employee of Novartis. I.M. received grants and research support from
Merck, Roche, Pfizer and Bristol-Myers Squibb. J.S. received grants
and research support from Pfizer, Merck, Abbott, sanofi-aventis and
Bristol-Myers Squibb, and is a member of the speakers bureaus of
Roche, Pfizer, Merck, Abbott, sanofi-aventis and Bristol-Myers
Squibb. D.V. received grants and research support from Abbott
Laboratories, Amgen, Bristol-Myers Squibb, Centocor, Chugai, Merck,
Novartis, Pfizer, Roche, sanofi-aventis, Schering-Plough, UCB and
Wyeth, and is a consultant to Abbott, Amgen, Bristol-Myers Squibb,
Centocor, Chugai, Merck, Novartis, Pfizer, sanofi-aventis, Schering-
Plough, UCB and Wyeth. B.W. is a member of the speakers bureaus of
Abbott and Merck. A.W. is an employee of Novartis. All other authors
have declared no conflicts of interest.
O12. TOCILIZUMAB AS MONOTHERAPY OR IN
COMBINATION WITH METHOTREXATE ASSOCIATED WITH
EARLY REDUCTIONS IN TISSUE INFLAMMATION: 12 WEEK
RESULTS FROM A MAGNETIC RESONANCE IMAGING
SUBSTUDY OF A RANDOMIZED CONTROLLED TRIAL
Philip G. Conaghan1, Charles G. Peterfy2, Julie DiCarlo2,
Ewa Olech3, Alan R. Alberts4, Jeffrey A. Alper5, Jenny Devenport6,
Andrew M. Anisfeld6 and Orrin M. Troum7
1NIHR-Leeds Biomedical Research Unit and Leeds Institute of
Molecular Medicine, University of Leeds, Leeds, United Kingdom,
2Spire Sciences LLC, San Francisco, CA, USA, 3Oklahoma Medical
Research Foundation, Oklahoma City, OK, USA, 4West Broward
Rheumatology Associates, Inc., Tamarac, FL, USA, 5Jeffrey Alper
MD Research, Naples, FL, USA, 6Genentech, South San Francisco,
CA, 7USC Keck School of Medicine, Santa Monica, CA, USA
Background: Tocilizumab (TCZ) monotherapy is superior to metho-
trexate (MTX) in achieving clinical reduction of disease activity in
rheumatoid arthritis (RA). A 24 wk interim analysis of the phase 3b
ACT-RAY study showed no additional clinical benefit from adding MTX
to TCZ vs TCZþplacebo (PBO). This analysis describes magnetic
resonance imaging (MRI) measures of synovitis (SYN), osteitis (OST), &
erosion (ERO) through wk 12 after therapy initiation.
Methods: In the ACT-RAY study, RA patients (pts) with inadequate
response to MTX were randomized to continue stable MTX or receive
PBO, both in combination with TCZ 8 mg/kg IV every 4 wks. In a
substudy of this trial (N¼63), 0.2T extremity MRI of one hand
(metacarpophalangeal joints 1-5) & wrist was acquired at baseline
(BL) & wks 2, 12, & 52. Change in scores from BL through wk 12 for the
TCZþMTX & TCZþPBO groups are compared to evaluate early
effects of treatment on joint inflammation.
Results: Both groups showed high disease severity & burden at BL
(Table). By wk 2, decreases in SYN & OST were observed & became
statistically significant in both gps by wk 12. There were no significant
changes from BL in mean ERO. In the PBO group, BL OST scores
were higher. The proportion of patients who experienced improve-
ments ( Smallest Detectable Change (SDC)) for both SYN & OST was
higher in the PBO group than in the MTX gp. Similar pt numbers
experienced ERO progression vs regression in each group (Table).
No pt in the TCZþPBO group & only 1 (3.3%) patient in the
TCZþMTX group developed a newly eroded bone.
Conclusions: MRI data demonstrate that TCZ is associated with early
suppression of SYN and OST, with no mean increase in ERO score
through wk 12. Continuation of MTX in combination with TCZ or
switching to TCZ monotherapy are equally beneficial for early
suppression of joint inflammation. TCZ monotherapy may be an
appropriate option for pts intolerant or unwilling/unable to take MTX.
References
1. Jones G, Sebba A, Gu J et al. Comparison of tocilizumab
monotherapy versus methotrexate monotherapy in patients with
moderate to severe rheumatoid arthritis: the AMBITION study. Ann
Rheum Dis 2010;69:88–96.
2. Dougados M. Tocilizumab (TCZ) plus Methotrexate (MTX) does not
have superior clinical efficacy to TCZ alone in RA patients with
inadequate response to MTX: 24-Week results of the ACT-Ray
study. Submitted to EULAR 2011.
TABLE Mean values and SDC-based classification of RAMRIS scores
TCZþMTX (n¼ 31) TCZþPBO (n¼ 32)
Mean
RAMRIS
Score
BL
(n¼ 31)
Wk 2
(n¼ 31)
BL to wk2 
(95% CI)
(n¼ 31)
Wk 12
(n¼ 30)
BL to wk
12  (95% CI)
(n¼30)
BL
(n¼ 32)
Wk 2
(n¼ 32)
BL to wk2 
(95% CI)
(n¼ 32)
Wk 12
(n¼ 29)
BL to wk 12 
(95% CI) (n¼29)
SYN 7.2 7.1 0.1 (0.5,0.3) 6.3 0.9* (1.6,-0.2) 7.4 6.5 0.9# (1.5,0.4) 5.7 1.9** (2.8,-1.0)
OST 7.8 7.6 0.2* (1.3,0.9) 4.4 3.6# (6.5,-0.7) 11.1 10.3 0.7 (1.8,0.3) 5.5 5.1* (8.6,1.6)
ERO 19.4 19.4 0.0 (0.4,0.5) 19.2 0.3 (1.2, 0.6) 16.0 16.2 0.2 (0.0, 0.5) 16.6 0.0 (0.6,0.6)
 Change, *P 0.01, #P 0.001, **P0.0001. Wilcoxon signed rank test for no change from BL within group. Percentile interval: 95% CI of mean change from
BL within group.
TCZþMTX (n¼ 30) n (%) TCZþPBO (n¼29) n (%)
Classification derived from
SDC* at week 12
Regressors
(change -SDC)
Progressors
(change  SDC)
Regressors
(change -SDC)
Progressors
(change  SDC)
SYN 7 (23.3) 1 (3.3) 11 (37.9) 0
OST 6 (20.0) 0 9 (31.0) 1 (3.4)
ERO 3 (10.0) 2 (6.7) 3 (10.3) 2 (6.9)
* SDC values at wk 12: SYN 1.71, OST 4.27, ERO 1.51
iii24 Tuesday 1 May 2012, 11.30 – 13.00 BSR AND BHPR ORAL PRESENTATION OF ABSTRACTS
Tuesday 1 May 2012, 14.00 – 16.00
BSR AND BHPR PLENARY ABSTRACTS
BSR AND BHPR PLENARY ABSTRACTS
PA1. EPIDEMIOLOGY OF SPORTING INJURIES AMONG
ELITE SOCCER PLAYERS: A LONGITUDINAL STUDY
Philip Cooper1, Mo Gimpel3, Greg Deakin1, Karen Jameson1,
Malcolm Godtschailk3, Stephan Gadola2, Maria Stokes2 and
Cyrus Cooper1,2
1University of Southampton, MRC Lifecourse Epidemiology Unit,
Southampton, United Kingdom; 2NIHR Musculoskeletal BRU,
University of Southampton, Southampton, United Kingdom;
3Department of Sports Medicine, Southampton Football Club,
Southampton, United Kingdom
Background: Effective preventive strategies against musculoskeletal
injuries among elite athletes require knowledge of their incidence and
risk factors. We report a three year longitudinal register-based study of
sporting injuries among a cohort of soccer players registered at a
single professional club.
Methods: Data were maintained on all musculoskeletal sporting
injuries sustained among all 272 elite players registered over the three
year period 2007-10, at a single professional football club. Players
were included from schoolboy (under-12), scholars (16-18), develop-
ment (18-21) and first team (16þ years) squads, over the study period.
Data included the date, type, severity and impact of injuries.
Results: 477 injury episodes were experienced by 131 players over
the observation period (incidence 48.2% per year of follow-up; first
team 65.2%; development 10.4%; scholar 21.4%; and schoolboy
71.4%). Multiple injuries in the same player were frequent at all ages.
The most frequent injuries occurred at the ankle (16%), knee (14.8%),
as well as muscular strains of the four major lower limb muscle groups
(27.9%). At the ankle, ligamentous strains accounted for 53% of the
injuries; at the knee, the corresponding proportion of ligamentous
injury was 35%. Similar proportions and grades of injury were
observed in training and match situations; however, there was a
significant (p< 0.05) excess of injuries in the last quarter of training
periods. In a logistic regression model, significant determinants of
injury severity included tissue (ligament v muscular OR 7.5; 95%CI 3.3-
16.9); site (knee OR 15.5; 95%CI 2.9-82.9); and direct trauma (OR 3.3;
95%CI 1.5-7.3). Activities significantly (p<0.05) associated with injury
severity included changing direction, tackling, landing from a jump and
collision.
Conclusions: Musculoskeletal injury is frequent among elite soccer
players and become apparent at early stages of post-pubertal
development (schoolboy, development squad) as well as among
senior team players. Injuries cluster in individuals at all age groups
studied, and are often limit further participation. Strategies to reduce
such injuries need to focus on both the mechanism of trauma, as well
as individual susceptibility. The injury database developed for this
study will provide a basis for future evaluation of such strategies.
Disclosure statement: All authors have declared no conflicts of
interest.
PA2. EPRATUZUMAB DEMONSTRATES CLINICALLY
MEANINGFUL IMPROVEMENTS IN PATIENTS WITH
MODERATE-TO-SEVERE SYSTEMIC LUPUS
ERYTHEMATOSUS: RESULTS FROM EMBLEM½,
A PHASE IIB STUDY
Caroline Gordon1, K. Kalunian2, M. Petri3, V. Strand4, B. Kilgallen5,
A. Barry5 and D. Wallace6
1Rheumatology, University of Birmingham, Birmingham, United
Kingdom; 2University of California, San Diego, School of Medicine,
La Jolla, California, United States of America; 3Medicine, The Johns
Hopkins University, Baltimore, Maryland, United States of America;
4Division of Immunology and Rheumatology, Stanford University,
Palo Alto, California, United States of America; 5UCB Inc., Smyrna,
Georgia, United States of America; 6Medicine, Cedars-Sinai Medical
Center and UCLA School of Medicine, Los Angeles, California,
United States of America
Background: Epratuzumab (Emab) is a novel, humanized, anti-CD22
monoclonal antibody under development for the treatment of active
SLE. The 12-wk, multicentre, Phase IIb, randomized, double-blind,
placebo-controlled study (NCT00624351) discussed here was
designed to evaluate the efficacy and safety of Emab in SLE, and
identify an optimal dose and regimen for further studies.
Methods: Pts with moderate/severe SLE (1 BILAG 2004 A or 2 Bs)
were randomized to 1 of 6 intravenous regimens: placebo (PBO:
standard of care) or cumulative dose (cd) Emab (200, 800, 2400 or
3600 mg in equal divided doses using 2 every other wk [EOW] infusions
or 2400 mg cd as 4 equal infusions 1 wk apart). Both 2400 mg cd
groups (1200 mg EOW and 600 mg weekly) were also combined for
analysis. Concomitant oral corticosteroids/immunosuppressives were
to be stable before first infusion and during the study. Primary end-
point was a combined responder index of clinical disease activity at wk
12, defined as reduction of all baseline BILAG A to B/C/D and BILAG B
to C/D in all body systems, no BILAG worsening in other organ
systems, and no deterioration in SLEDAI or PGA, with no increase in
corticosteroids/immunosuppressives over baseline.
Results: At baseline, in the entire population (N¼227) mean age was
38.8 years, 94% were female, 78% Caucasian; with high disease
activity (70% with 1 BILAG A, mean total scores: BILAG 15.2,
SLEDAI 14.8). At wk 12, compared with the responder rate in the PBO
group (21.1%), responder rates were statistically greater in the Emab
600-mg weekly (2400 mg cd) (45.9%; p¼0.03) and 2400-mg com-
bined groups (43.2%; p¼0.02); and showed clinically meaningful
improvement in the 1200-mg EOW (2400 mg cd) group (Table 1). By
wk 12, 18.9% of pts in both 2400-mg cd groups achieved enhanced
BILAG improvement (improvement of all body systems to BILAG C or
better on consecutive visits, with no worsening) vs 13.2% in placebo.
Emab was well tolerated with an incidence of serious adverse events
and infusion reactions similar to PBO.
Conclusions: Emab cd 2400 mg demonstrated clinically meaningful
improvements in disease activity in pts with moderately to severely
active SLE at 12 wks, with responder rates twice those of PBO
(p¼0.02 to p¼ 0.07). Results validate the combined index emphasiz-
ing BILAG and support Phase III trials of Emab in SLE.
Disclosure statement: A.B. is an employee of UCB. C.G. received
consultancy fees from UCB, Roche, Genentech and Aspreva
Pharmaceuticals/Vifor Pharma, and grant/research support from
Aspreva Pharmaceuticals/Vifor Pharma. K.K. received grant/research
support from UCB, MedImmune, Genentech and NovoNordisk, and
consultancy fees from UCB, MedImmune, Genentech, NovoNordisk,
Zymogenetics and MerckSerono. B.K. is an employee of UCB. M.P.
received grant/research support from UCB, and is a consultant to
UCB. V.S. received consultancy fees from UCB. D.W. received
consultancy fees from UCB, Genetech, MedImmune, HGS,
NovoNordisk and BMS. All other authors have declared no conflicts
of interest.
TABLE 1.
Emab cd 200 mg Emab cd 800 mg Emab cd 2400 mg Emab cd 2400 mg Emab cd 2400 mg Emab cd 3600 mg
PBO (n¼ 38) 100 mg EOW
(n¼ 39)
400 mg EOW
(n¼ 38)
600 mg weekly
(n¼ 37*)
1200 mg EOW
(n¼ 37)
Combined group
(n¼ 74)
1800 mg EOW
(n¼38)
Responders
n (%)
8 (21.1) 12 (30.8) 10 (26.3) 17 (45.9) 15 (40.5) 32 (43.2) 9 (23.7)
1.7 (0.6-4.7) 1.3 (0.5-3.9) 3.2 (1.1-8.8) p¼ 0.03** 2.6 (0.9-7.1) p¼ 0.07** 2.9 (1.2-7.1) p¼ 0.02** 1.2 (0.4-3.4)
* 2 pts randomized but never received drug; ** p values not adjusted for multiple comparisons
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PA3. WILL I WASTE YOUR TIME?
DELAYS IN SEEKING HELP FOR RA
FLARES
Caroline A. Flurey1, Marianne Morris1,
Jon Pollock1, Rod Hughes3, Pam Richards2 and Sarah Hewlett1
1Faculty of Health and Life Sciences, University of the West of
England, Bristol, United Kingdom; 2Rheumatology, University
Hospitals Bristol, Bristol, United Kingdom; 3Rheumatology, St Peter’s
Hospital, Chertsey, United Kingdom
Background: Anecdotal evidence suggests that patients vary in how
long they wait before seeking medical help for an RA flare. The aim of
this research is to explore why, and their tipping points for seeking
help.
Methods: Q-Methodology: 29 RA patients sorted 23 statements
(generated in previous qualitative interviews) about their help seeking
behaviours when in a flare, across a forced distribution in ranked order
of agreement. Data were analysed using centroid factor analysis with
varimax rotation (i.e. the participants and not the items are the
variables). Demographic and clinical data were collected and patients
completed comments booklets about their rationale for sorting the
statements.
Results: Consensus was reached on 9 statements and two factors
were produced, which explained 51% of the study variance and
accounted for 22 of the 29 participants. None of the Q-sorts were
confounded (loading on more than one factor). A participant loading of
0.54 reached significance at p< .01.
Consensus: ‘‘When I just don’t know what to do anymore’’: The top
3 of the 9 consensus statements are ‘when the pain becomes too
intense’, ‘when the Flare has gone on longer than expected’ and ‘when
the symptoms become uncontrollable’, suggesting these are the
tipping points for seeking help.
Factor A: Definite Decision: ‘‘It won’t go away, so I won’t wait’’:
Sixteen participants: mean disease duration 15.2yrs (SD 10.3), age
54.8yrs (SD 9.6), HAQ score 1.360 (SD 0.8), 69% female, 69% on
biologic therapies.
These patients will seek help quickly when they are in a flare, they
know that their medical team can help and that their flare won’t go
away on its own. They don’t worry about wasting their own or the
Rheumatologist’s time and will not wait until their next scheduled
appointment for help. Tipping points for seeking help for these patients
are worries about long term damage to their joints, knowing their flare
needs to be controlled by new medication and their quality of life being
affected.
Factor B: Cautious Indecision: ‘‘Lying down and not moving until it
goes’’: Six participants: mean disease duration 18.7yrs (SD 13.9), age
50.5yrs (SD 15.4), HAQ score 1.23 (SD 0.9) 67% female, 0% on
biologic therapies.
These patients wait to contact the medical team when they are in a
flare. They are reluctant to seek help as they hope the flare will go
away on its own and do not believe it will last until they seek medical
help. They don’t like asking for help and worry about wasting the
Rheumatologist’s time. They may wait until their next scheduled
appointment before seeking help and will try to manage their
symptoms themselves. These patients need to be prompted by a
friend or family member to seek help.
Conclusions: Whilst consensus indicates pain is a tipping point, for
some patients a complex interaction of beliefs hinders their help-
seeking behaviour. Health care professionals should be aware that
some patients delay help-seeking due to fears of time wasting, thus
potentially risking further damage.
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